The tribunal's decision to dismiss Boehringer Ingelheim's indemnification claim against Sanofi and confirm that Sanofi shall not be liable for any potential losses in the ongoing Zantac litigation is positive news for Sanofi. This reduces potential financial liabilities for the company, which is likely to have a positive impact on its stock price in the short term.